Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1984 Aug;26(2):270–271. doi: 10.1128/aac.26.2.270

Activities of cefoxitin and cefotetan against Mycobacterium fortuitum infections in mice.

H Saito, K Sato, B W Jin
PMCID: PMC284136  PMID: 6592999

Abstract

Mice inoculated intravenously with Mycobacterium fortuitum 18367 were treated subcutaneously with cefoxitin or cefotetan once daily for 4 weeks, beginning 24 h after challenge. Both drugs suppressed spinning disease, and both reduced the severity of renal lesions and the number of organisms in the kidneys and liver but not in the lungs or spleen. These therapeutic effects were dose-dependent.

Full text

PDF
270

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bennett J. V., Brodie J. L., Benner E. J., Kirby W. M. Simplified, accurate method for antibiotic assay of clinical specimens. Appl Microbiol. 1966 Mar;14(2):170–177. doi: 10.1128/am.14.2.170-177.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cullmann W., Opferkuch W., Stieglitz M., Werkmeister U. A comparison of the antibacterial activities of N-formimidoyl thienamycin (MK0787) with those of other recently developed beta-lactam derivatives. Antimicrob Agents Chemother. 1982 Aug;22(2):302–307. doi: 10.1128/aac.22.2.302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dickinson G. M., Cleary T. J., Hoffman T. A. Comparative evaluation of piperacillin in vitro. Antimicrob Agents Chemother. 1978 Dec;14(6):919–921. doi: 10.1128/aac.14.6.919. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fu K. P., Neu H. C. Piperacillin, a new penicillin active against many bacteria resistant to other penicillins. Antimicrob Agents Chemother. 1978 Mar;13(3):358–367. doi: 10.1128/aac.13.3.358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. GORRILL R. H. Bacterial localisation in the kidney with particular reference to Pseudomonas pyocyanea. J Pathol Bacteriol. 1952 Oct;64(4):857–864. doi: 10.1002/path.1700640417. [DOI] [PubMed] [Google Scholar]
  6. Gribble M. J., Chow A. W., Naiman S. C., Smith J. A., Bowie W. R., Sacks S. L., Grossman L., Buskard N., Growe G. H., Plenderleith L. H. Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infections. Antimicrob Agents Chemother. 1983 Sep;24(3):388–393. doi: 10.1128/aac.24.3.388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hallander H. O., Dornbusch K., Gezelius L., Jacobson K., Karlsson I. Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method. Antimicrob Agents Chemother. 1982 Nov;22(5):743–752. doi: 10.1128/aac.22.5.743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jones R. N., Packer R. R., Barry A. L., Badal R. E., Thornsberry C., Baker C. Piperacillin (T-1220), a new semisynthetic penicillin. II. In vitro antimicrobial activity and synergy comparison with carbenicillin and gentamicin. J Antibiot (Tokyo) 1979 Jan;32(1):29–35. doi: 10.7164/antibiotics.32.29. [DOI] [PubMed] [Google Scholar]
  9. KUSHNER D. S., MCMILLEN S., SENDERI M. Atypical acid-fast bacilli. II. Mycobacterium fortuitum: bacteriologic characteristics and pathogenicity for laboratory animals. Am Rev Tuberc. 1957 Jul;76(1):108–122. doi: 10.1164/artpd.1957.76.1.108. [DOI] [PubMed] [Google Scholar]
  10. Kahan J. S., Kahan F. M., Goegelman R., Currie S. A., Jackson M., Stapley E. O., Miller T. W., Miller A. K., Hendlin D., Mochales S. Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties. J Antibiot (Tokyo) 1979 Jan;32(1):1–12. doi: 10.7164/antibiotics.32.1. [DOI] [PubMed] [Google Scholar]
  11. Kropp H., Sundelof J. G., Kahan J. S., Kahan F. M., Birnbaum J. MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities. Antimicrob Agents Chemother. 1980 Jun;17(6):993–1000. doi: 10.1128/aac.17.6.993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Miller M. A., Finan M., Yousuf M. In-vitro antagonism by N-formimidoyl thienamycin and cefoxitin of second and third generation cephalosporins in Aeromonas hydrophila and Serratia marcescens. J Antimicrob Chemother. 1983 Apr;11(4):311–318. doi: 10.1093/jac/11.4.311. [DOI] [PubMed] [Google Scholar]
  13. Neu H. C., Labthavikul P. Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability. Antimicrob Agents Chemother. 1982 Jan;21(1):180–187. doi: 10.1128/aac.21.1.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. O'Callaghan C. H., Morris A., Kirby S. M., Shingler A. H. Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate. Antimicrob Agents Chemother. 1972 Apr;1(4):283–288. doi: 10.1128/aac.1.4.283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Saito H., Tasaka H. Comparison of the pathogenicity for mice of Mycobacterium fortuitum and Mycobacterium abscessus. J Bacteriol. 1969 Sep;99(3):851–855. doi: 10.1128/jb.99.3.851-855.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Sanders C. C. Novel resistance selected by the new expanded-spectrum cephalosporins: a concern. J Infect Dis. 1983 Mar;147(3):585–589. doi: 10.1093/infdis/147.3.585. [DOI] [PubMed] [Google Scholar]
  17. Sanders C. C., Sanders W. E., Jr Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamases and implications for the future. Rev Infect Dis. 1983 Jul-Aug;5(4):639–648. doi: 10.1093/clinids/5.4.639. [DOI] [PubMed] [Google Scholar]
  18. Simon G. L., Snydman D. R., Tally F. P., Gorbach S. L. Clinical trial of piperacillin with acquisition of resistance by Pseudomonas and clinical relapse. Antimicrob Agents Chemother. 1980 Jul;18(1):167–170. doi: 10.1128/aac.18.1.167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Tice A. D., Solomon R. J. Disseminated Mycobacterium chelonei infection: response to sulfonamides. Am Rev Respir Dis. 1979 Jul;120(1):197–201. doi: 10.1164/arrd.1979.120.1.197. [DOI] [PubMed] [Google Scholar]
  20. Wallace R. J., Jr, Jones D. B., Wiss K. Sulfonamide activity against Mycobacterium fortuitum and Mycobacterium chelonei. Rev Infect Dis. 1981 Sep-Oct;3(5):898–904. doi: 10.1093/clinids/3.5.898. [DOI] [PubMed] [Google Scholar]
  21. Winston D. J., Murphy W., Young L. S., Hewitt W. L. Piperacillin therapy for serious bacterial infections. Am J Med. 1980 Aug;69(2):255–261. doi: 10.1016/0002-9343(80)90386-1. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES